UCLA's 565-Study Review Finds the Evidence Gap in Popular Research Peptides
TL;DR: A UCLA review of 565 studies found little reliable evidence that BPC-157, TB-500, GHK-Cu and other peptide supplements are effective.
What Did UCLA's 2026 Review of Peptide Supplements Examine?
Peptide Supplements and Their Therapeutic Applications in Sports Medicine, published in the American Journal of Sports Medicine in 2026 and publicised by UCLA Health on 8 September 2026, is one of the largest literature audits yet assembled on the peptides most heavily marketed for recovery, tissue repair and performance.[1] The authors — Kushagra Tewari, Timothy P. Liu, Christina Im, Christopher Hamad, Frank Petrigliano, Edward C. Cheung and Thomas J. Kremen, all affiliated with the David Geffen School of Medicine at UCLA — screened 565 studies examining six compounds' effects on musculoskeletal treatment, tissue recovery or performance in animal or human models.[2]
The scope covers exactly the compounds most frequently discussed by researchers and stocked by suppliers such as Velox Peptides: BPC-157, TB-500, CJC-1295, ipamorelin and GHK-Cu, plus the growth-hormone secretagogue MK-677 (ibutamoren), which is not stocked by Velox but was included in the review's six-peptide set.[1] Lead investigator Thomas Kremen summarised the team's conclusion bluntly: "The evidence that these peptides are effective is just not there."[2]
How Was the Review Conducted, and What Did It Find Overall?
The team searched the published literature for human and animal studies of the six peptides and screened them for relevance to musculoskeletal treatment, tissue recovery or athletic performance, arriving at 565 qualifying studies.[1] More than two-thirds were conducted only in animals, and the limited human research that did exist was generally judged low quality.[2] Where animal data did show an effect — on tendon, muscle, bone or ligament healing — the authors cautioned that those effects can look very different in rodents than in humans, and that essentially no studies demonstrated a significant clinical benefit for musculoskeletal conditions in people.[2]
David Geffen School of Medicine, UCLA. Literature review of 565 human and animal studies covering BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu. Findings publicised by UCLA Health/UCLA Newsroom, 8 September 2026.[1]
American Journal of Sports Medicine, 2026. DOI: 10.1177/03635465261464420
The review also flagged a research-integrity issue that is easy to overlook amid the efficacy debate: one of the largest studies conducted on BPC-157 involved a research group with a disclosed financial interest in the compound itself — a conflict the authors say should factor into how that data is weighted.[2]
What Does the Review Say About BPC-157, TB-500 and GHK-Cu?
For BPC-157 and TB-500, the pattern the review describes is consistent with what we have covered previously on this site: a substantial preclinical literature showing angiogenic and tissue-repair signalling in animal models, alongside a human evidence base that remains thin and largely uncontrolled.[2] As we detailed in our guide to the 2026 JBJS Reviews evidence audit of the same compound class, no properly randomised, placebo-controlled human trial of BPC-157 had reached active recruitment until early 2026 — so for most of the period UCLA's team screened, the available human data consisted of small or single-arm reports rather than the controlled trials researchers need to establish efficacy.
GHK-Cu was assessed on the same terms: promising mechanistic and animal-model signalling for tissue remodelling, but a human evidence base the review did not find sufficient to support the therapeutic claims increasingly attached to it in consumer marketing.[1] The review's framing is not that the underlying biology is implausible — the preclinical literature it draws on is extensive — but that plausibility, animal data and controlled human proof remain three distinct things, and for this compound class the third is still largely missing.
What About CJC-1295, Ipamorelin and MK-677?
CJC-1295, ipamorelin and MK-677 act on growth-hormone-axis pathways — the first two via the GHRH or ghrelin receptor systems, MK-677 as an oral ghrelin-receptor agonist. The review found the same shortage of controlled human efficacy data for musculoskeletal or recovery applications that it documented for the regenerative peptides, but for MK-677 it also surfaced a specific safety signal worth flagging on its own.[2]
| Peptide | Human efficacy evidence | Flagged safety/integrity issue |
|---|---|---|
| BPC-157 | Limited, largely uncontrolled | Financial conflict in a major study |
| TB-500 | Limited, largely preclinical | None specifically flagged |
| GHK-Cu | Preclinical/mechanistic only | None specifically flagged |
| CJC-1295 / ipamorelin | No RCT evidence for MSK/recovery use | None specifically flagged |
| MK-677 (ibutamoren) | No RCT evidence for MSK/recovery use | Congestive heart failure signal; impaired glucose tolerance |
The MK-677 finding traces to a previously published randomised trial in older adults recovering from hip fracture: 25 mg daily improved gait speed relative to placebo, but 6.5% of the MK-677 group developed congestive heart failure versus 1.7% on placebo — a difference serious enough that the trial was discontinued.[3] The review cites this alongside impaired glucose tolerance as documented safety concerns for the compound, on top of the same efficacy gap that applies across the class.[2]
How Does This Compare With Licensed Pharmaceutical Peptides?
The contrast UCLA's team draws implicitly is the same one earlier literature audits have made explicitly: peptide classes that have been through large, multi-year, randomised trial programmes — the kind pharmaceutical development requires — look nothing like the six consumer-marketed peptides this review assessed. GLP-1/GIP/glucagon agents such as retatrutide, currently in Phase 3 development, have generated exactly the reproducible randomised datasets that BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu still lack for their marketed uses. That is not a comment on the underlying biology of either group — it is a comment on which compounds have been through the trial infrastructure needed to generate proof, and which have not.
Marketing outpacing the science
UCLA's own summary of the findings, published as "With peptide supplements, marketing outpaces the medicine," states plainly that claims made for these six peptides have moved faster than the evidence supporting them.[1]
Unregulated consumer market
The authors note that products sold directly to consumers for these peptides are unapproved and unregulated, and may contain undisclosed or inaccurate active ingredient — a finding consistent with independent testing of seized and gray-market peptide products covered elsewhere on this site.
Research quality, not just quantity
The review's central point is not simply that human trials are scarce, but that the trials which do exist are frequently small, uncontrolled or subject to undisclosed financial interests — a quality problem that more studies alone will not fix.[2]
What Should UK Researchers Take From This?
This review is a literature audit, not a new dataset — it tests no product and changes nothing about the underlying preclinical pharmacology of BPC-157, TB-500, CJC-1295, MK-677, ipamorelin or GHK-Cu. What it does provide is an independent, peer-reviewed benchmark confirming how thin the controlled human evidence base remains for this compound class, and a specific warning — the MK-677 cardiac signal — that safety data deserves as much scrutiny as efficacy claims.
For UK-based researchers, the distinction this site makes consistently still holds: a reagent supplied with batch-level HPLC verification, sold explicitly for laboratory use and never represented as a finished drug product, sits in a different category from an unverified vial marketed for self-administration on the strength of preclinical data alone. The evidence gaps this review documents are precisely why properly controlled research, using correctly characterised material, remains the priority the authors themselves identify.
All compounds named are supplied as research reagents only. None is a medicine and none has been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- UCLA Health / UCLA Newsroom. With Peptide Supplements, Marketing Outpaces the Medicine. 8 September 2026. uclahealth.org/news/article/with-peptide-supplements-marketing-outpaces-medicine
- Tewari K, Liu TP, Im C, Hamad C, Petrigliano F, Cheung EC, Kremen TJ. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. American Journal of Sports Medicine. 2026. DOI: 10.1177/03635465261464420
- Adunsky A, et al. Randomised controlled trial of ibutamoren (MK-677) in older adults following hip fracture repair, cited as the source of the reviewed congestive-heart-failure safety signal (6.5% MK-677 vs 1.7% placebo). 2011.
- Velox Peptides. What a 2026 Sports-Medicine Review Found About Injectable Research Peptides. See our JBJS Reviews evidence-audit guide for the companion literature review covering BPC-157, TB-500, CJC-1295, ipamorelin and tesamorelin.
Frequently Asked Questions
What did UCLA's 2026 review of peptide supplements find?
UCLA orthopaedic-surgery researchers reviewed 565 published studies of six peptides marketed for recovery and performance — BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu — and concluded that the evidence these compounds are effective in humans is not there. More than two-thirds of the studies were animal-only, the human research was generally low quality, and the authors flagged a financial conflict of interest in one influential BPC-157 study and a serious cardiac safety signal in an MK-677 trial.
Which journal published the review and who conducted it?
The review, titled Peptide Supplements and Their Therapeutic Applications in Sports Medicine, was authored by Kushagra Tewari, Timothy P. Liu, Christina Im, Christopher Hamad, Frank Petrigliano, Edward C. Cheung and Thomas J. Kremen of the David Geffen School of Medicine at UCLA, and published in the American Journal of Sports Medicine in 2026. UCLA Health publicised the findings on 8 September 2026.
What does the review say about BPC-157 and TB-500 specifically?
The review found promising but variable tendon, muscle, bone and ligament-healing signals for BPC-157 and TB-500 in animal models, but said effects seen in rodents may not translate to humans and that essentially no studies demonstrated a significant clinical benefit for musculoskeletal conditions in people. The authors also noted that one of the largest BPC-157 studies involved researchers with a financial interest in the compound.
Why was an MK-677 trial stopped early?
The review cites a randomised trial in which older adults with hip fracture given MK-677 (ibutamoren) 25 mg daily saw improved gait speed, but 6.5% of the MK-677 group developed congestive heart failure versus 1.7% on placebo — a safety signal serious enough that the trial was discontinued. The authors list impaired glucose tolerance as a further documented concern across this peptide class.
Does this review affect Velox Peptides' research-grade supply?
No. The review assesses published human and animal evidence for peptides marketed directly to consumers and athletes. Velox Peptides supplies BPC-157, TB-500, CJC-1295, ipamorelin and GHK-Cu solely as HPLC-verified in vitro research reagents, with batch-level documentation, for qualified researchers investigating the same mechanisms this review discusses — never as a finished drug product and never represented as approved or fit for human administration.